# DRUG MASTER FILE
## Phenylpiracetam (R-Phenylpiracetam)

**DMF Number:** DMF-2025-001847  
**Submission Date:** July 23, 2025  
**DMF Type:** Type II - Drug Substance  
**Applicant:** DataPharma Research Solutions LLC  

---

## 1. ADMINISTRATIVE INFORMATION

**Product Name:** Phenylpiracetam  
**Chemical Name:** (R)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide  
**Common Names:** Phenotropil, Carphedon, 4-phenylpiracetam  
**CAS Registry Number:** 77472-70-9  
**Molecular Formula:** C₁₂H₁₄N₂O₂  
**Molecular Weight:** 218.25 g/mol  

**Therapeutic Category:** Nootropic agent / Cognitive enhancer  
**Proposed Use:** Cognitive function enhancement, memory improvement  

---

## 2. DRUG SUBSTANCE INFORMATION

### 2.1 Structure and Properties

**Chemical Structure:**
```
    O
    ║
H₂N-C-CH₂-N
           │   \
           │    \
           │     CH₂
           │    /
           │   /
          CH-CH₂
         /
    Ph-C
```

**Physical Properties:**
- **Appearance:** White to off-white crystalline powder
- **Melting Point:** 149-151°C
- **Solubility:** 
  - Water: Slightly soluble (0.8 mg/mL at 25°C)
  - Ethanol: Freely soluble
  - DMSO: Soluble
- **pH:** 6.0-7.0 (1% aqueous solution)
- **Partition Coefficient (log P):** 1.23
- **pKa:** 14.2 (predicted)

### 2.2 Stereochemistry
- **Chirality:** Single chiral center at C-4 of pyrrolidinone ring
- **Configuration:** R-enantiomer (active form)
- **Enantiomeric Excess:** ≥98% R-enantiomer

---

## 3. MANUFACTURING INFORMATION

### 3.1 Manufacturing Process Overview
**Process Type:** Multi-step organic synthesis  
**Key Steps:**
1. Friedel-Crafts acylation of benzene with succinic anhydride
2. Cyclization to form phenyl-substituted pyrrolidinone
3. Amidation reaction to introduce acetamide group
4. Chiral resolution to obtain R-enantiomer
5. Crystallization and purification

### 3.2 Critical Process Parameters
- **Temperature Control:** ±2°C during cyclization step
- **pH Control:** 7.5-8.0 during amidation
- **Reaction Time:** 4-6 hours for key transformations
- **Moisture Control:** <0.5% throughout process

### 3.3 Manufacturing Site
**Primary Manufacturer:** Synthetic Solutions International  
**Address:** 1247 Chemical Valley Road, Houston, TX 77002  
**GMP Certification:** FDA registered, EU GMP certified  
**Capacity:** 500 kg/year

---

## 4. QUALITY CONTROL SPECIFICATIONS

### 4.1 Release Specifications

| Parameter | Specification | Test Method |
|-----------|---------------|-------------|
| **Appearance** | White to off-white crystalline powder | Visual inspection |
| **Identity** | Conforms to reference standard | HPLC, NMR, IR |
| **Assay** | 98.0-102.0% | HPLC-UV (270 nm) |
| **Enantiomeric Purity** | ≥98% R-enantiomer | Chiral HPLC |
| **Related Substances** | ≤2.0% total impurities | HPLC-UV |
| **Water Content** | ≤0.5% | Karl Fischer |
| **Residual Solvents** | Per ICH Q3C limits | GC-HS |
| **Heavy Metals** | ≤10 ppm | ICP-MS |
| **Microbial Limits** | <100 CFU/g total aerobic | USP <61> |
| **Particle Size** | D90 ≤ 100 μm | Laser diffraction |

### 4.2 Stability Data Summary
- **Long-term:** 24 months at 25°C/60% RH (ongoing)
- **Accelerated:** 6 months at 40°C/75% RH (stable)
- **Stress Testing:** Stable under ICH Q1A conditions
- **Photostability:** Stable under ICH Q1B conditions
- **Retest Period:** 36 months (proposed)

---

## 5. IMPURITY PROFILE

### 5.1 Identified Impurities

| Impurity | Structure Description | Specification | Origin |
|----------|----------------------|---------------|---------|
| **Imp-A** | S-Phenylpiracetam | ≤1.0% | Chiral impurity |
| **Imp-B** | 4-Phenylpyrrolidin-2-one | ≤0.5% | Synthesis intermediate |
| **Imp-C** | N-oxide derivative | ≤0.3% | Oxidative degradant |
| **Imp-D** | Dimeric impurity | ≤0.2% | Process-related |

### 5.2 Genotoxicity Assessment
- All impurities <0.5% are below TTC limits (1.5 μg/day)
- S-enantiomer (Imp-A): AMES negative, acceptable at ≤1.0%

---

## 6. ANALYTICAL METHODS

### 6.1 HPLC Assay Method
**Column:** Phenomenex Luna C18, 250 × 4.6 mm, 5 μm  
**Mobile Phase:** 70:30 Phosphate buffer (pH 3.0):Acetonitrile  
**Flow Rate:** 1.0 mL/min  
**Detection:** UV at 270 nm  
**Runtime:** 15 minutes  
**Validation Status:** Fully validated per ICH Q2(R1)

### 6.2 Chiral HPLC Method
**Column:** Chiralpak AD-H, 250 × 4.6 mm, 5 μm  
**Mobile Phase:** 90:10:0.1 Hexane:Isopropanol:Diethylamine  
**Flow Rate:** 1.0 mL/min  
**Detection:** UV at 254 nm  
**Resolution:** >2.0 between enantiomers

---

## 7. PACKAGING AND STORAGE

**Primary Packaging:** Double polyethylene bags  
**Secondary Packaging:** Fiber drums with polyethylene liner  
**Pack Sizes:** 1 kg, 5 kg, 25 kg  
**Storage Conditions:** Store at 15-25°C, protect from light and moisture  
**Shelf Life:** 36 months under recommended storage conditions  

---

## 8. REGULATORY STATUS

**FDA Status:** GRAS notification pending  
**International:** No current marketing authorizations  
**Patents:** US Patent 9,123,456 (expires 2039)  
**Freedom to Operate:** Clear for research applications  

---

## 9. ENVIRONMENTAL IMPACT

**Environmental Fate:** Readily biodegradable  
**Aquatic Toxicity:** LC50 >100 mg/L (fish)  
**Waste Streams:** Incineration recommended for solid waste  

---

## 10. SUPPORTING DOCUMENTATION

### 10.1 Attached Documents
- Certificate of Analysis (typical)
- Stability study protocol and reports
- Method validation reports
- Impurity synthesis and characterization
- Environmental assessment report
- GMP certificates for manufacturing site

### 10.2 Cross-References
- **Related DMFs:** None  
- **INDs:** IND-2024-789012 (Phase I cognitive study)  
- **NDAs:** None submitted  

---

**Document Control:**  
Version: 1.0  
Effective Date: July 23, 2025  
Next Review Date: July 23, 2026  
Prepared by: Dr. Sarah Chen, Regulatory Affairs  
Reviewed by: Dr. Michael Rodriguez, Quality Assurance  
Approved by: Jennifer Walsh, Vice President, Regulatory